Global Hypertension in CKD Market to Surpass US$ 388.3 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global hypertension in CKD market is estimated to be valued at US$ 191.8 million in 2020 and is expected to exhibit a CAGR of 10.6% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Hypertension in CKD Market:

Key trends in the market include increasing research and development activities, product launches, regulatory approvals, and others.

Key players are involved in receiving approval from the regulatory authorities for the treatment of hypertension in the patients suffering from chronic kidney disease. This is expected to spur the growth of the market over the forecast period. For instance, on February 6, 2021, AstraZeneca Plc received approval from Drugs Controller General of India (DCGI) for Dapagliflozin tablets for the treatment of patients suffering from hypertension in chronic kidney disease.

Market players are engaged in submitting New Drug Application to the regulatory authorities for the treatment hypertension in CKD patients. For instance, on June 30, 2020 Ardelyx submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of tenapanor for the treatment of hyperphosphatemia in the U.S. According to the National Center for Biotechnology Information: 2018, hyperphosphatemia in dialysis patients is associated with vascular wall stiffness, which leads to hypertension.

Request for Sample copy of report @ https://www.coherentmarketinsights.com/insight/request-sample/4431

Market players are indulged in gaining Fast Track Designation for the drugs from the regulatory authorities, which is expected to drive growth of the global hypertension in CKD market over the forecast period. For instance, on March 12, 2020, C.H. Boehringer Sohn AG & Ko. KG and Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) Fast Track designation grant for conducting clinical trial of empagliflozin, in order to check its pharmacokinetics, safety, and efficacy in reducing the risk of kidney disease progression and cardiovascular death in adults suffering from chronic kidney disease.

Key Market Takeaways:

Increasing product launches by the market players is expected to drive the growth of the global hypertension in CKD market over the forecast period. For instance, in 2019, Mankind Pharma launched anti-hypertensive-drug Zolahart (Azilsartan), which is indicated for 24 hours blood pressure control. It has been found to be effective in the hypertensive patients with comorbid conditions like diabetes and CKD. It belongs to the Angiotensin-receptor-blocker class.

Among regions, North America is expected to hold a dominant position in the global hypertension in CKD market over the forecast period, owing to increasing prevalence of CKD in this region. For instance, according to the Centers for Disease Control and Prevention: 2019, in 2019, approximately 15% women and 12% men were suffering from CKD in the U.S. Moreover, in 26% of the cases, hypertension was the main cause for end-stage renal disease cases.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4431

Competitive Landscape:

Key players operating in the global hypertension in CKD market include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited.

Market Segmentation:

• Global Hypertension in CKD Market, By Drug Class:
  • Diuretics
  • RAS Blockade
  • β - Blockers
  • Calcium Channel Blockers
  • Others
• Global Hypertension in CKD Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Hypertension in CKD Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • By Country:
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005506/en/

Global #Hypertension in #CKD market is projected to grow at a CAGR of 10.6% during the forecast period 2020-2027, Says Coherent Market Insights